Clementine Sarkozy

Clementine Sarkozy

Versailles, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

Journal: The Lancet. Haematology

Published: February 18, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood

Published: January 13, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood

Published: January 13, 2026

All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?

All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 21, 2025

Optimizing bridging radiotherapy prior to CAR-T cell therapy: An evidence-based approach.

Optimizing bridging radiotherapy prior to CAR-T cell therapy: An evidence-based approach.

Journal: Critical reviews in oncology/hematology

Published: June 18, 2025

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Journal: Blood advances

Published: June 02, 2025

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 29, 2025

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Journal: Cancer discovery

Published: May 18, 2025

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Journal: Cancer discovery

Published: May 18, 2025

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 17, 2025

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Journal: Blood

Published: November 18, 2024

Showing 1-12 of 92

Last Updated: 09/26/2026